Skip to content

ONCY

Oncolytics Biotech, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$0.43
−3.15%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
-30.5%
EBIT
-29.7%
EPS
+6.2%
Free cash flow
-24.6%
Operating cash flow
-24.7%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
+25.4%

Three-year CAGR

Revenue
—
EBITDA
-12.6%
EBIT
-12.5%
Net income
-26.2%
EPS
-36.7%
Free cash flow
-0.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026